Peer-influenced content. Sources you trust. No registration required. This is HCN.
ACP Internist
On exam, this 19-year-old woman has malar rash characterized by pink-violet papules and plaques with no other physical finding. ANA is positive and urinalysis is remarkable for 3+ blood and protein. What test is the most appropriate next step?
Dermatology January 25th 2023
Annals of Internal Medicine
A layered approach to care is described with lifestyle interventions being a key feature of the updated recommendations. The recommendations now include therapies proven to improve cardiovascular and kidney outcomes in patients with diabetes and CKD.
Cardiology January 19th 2023
Medical Professionals Reference (MPR)
Sunlenca (lenacapavir), which comes in 300 mg tablets and a 463.5 mg/1.5 mL injection, provides doctors with a long-needed twice-yearly option for patients with complicated past treatment histories who would otherwise have few treatment options.
Allergy & Immunology January 11th 2023
MDLinx
Manuka honey contains amino acids, B-vitamins, calcium, copper, iron, magnesium, potassium, sodium, and zinc. It has antibacterial, antiviral, anti-inflammatory, and antioxidant properties. Besides use in wound infection, it may be useful in treating some GI disorders and sore throats.
Family Medicine/General Practice November 29th 2022
Cleveland Clinic Journal of Medicine (CCJM)
The timing of re-initiation of antithrombotic therapy needs to be individualized based on the severity of the bleed, among other factors. This article reviews the issue and offers tools and guidelines for determining if and when to restart antiplatelet and oral anticoagulant therapy.
Gastroenterology November 29th 2022
Clinical Oncology News
The FOENIX*-CCA2 trial, a global phase 2, open-label trial examining 103 patients with unresectable, locally progressed, or metastatic iCCA harboring FGFR2 gene rearrangements including fusions, was the basis for the approval of futibatinib (Lytgobi, Taiho Oncology). Patients in this trial received 20 mg of futibatinib orally once daily until disease progression or intolerable toxicity; the primary end goal was achieved with a 42% objective response rate as determined by an impartial central evaluation. With 72% of responses lasting at least six months, the median response time was 9.7 months.
Hepatology October 31st 2022